SCHEMBL1332508

SCHEMBL1332508

O=CC(O)(O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 2/20 0.41
ALDH1A1 P00352 5/20 0.39
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
CYP2C19 P33261 2/20 0.39
PTPN1 P18031 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNN4 O15554 4/20 0.38
TSHR P16473 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP2A6 P11509 1/20 0.38
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HIF1A Q16665 1/20 0.37
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863162 0.79 KDM4E (0.44) CYP2C9CYP1A2ALDH1A1ESR1ESR2
SCHEMBL9302742 0.79 ESR1 (0.48) ALDH1A1ESR1ESR2CYP3A4MAPT
SCHEMBL2172033 0.77 MEN1 (0.52) CYP1A2CYP3A4MAPTKMT2ATSHR
SCHEMBL3825948 0.77 KCNN4 (0.46) CYP2C9CYP2C19CYP3A4MAPTKMT2A
SCHEMBL28628134 0.76 CYP1A2 (0.41) CYP2C9CYP1A2ALDH1A1ESR1ESR2
SCHEMBL11516565 0.75 LMNA (0.58) CYP1A2CYP2C19PTPN1MAPTHIF1A
SCHEMBL10837928 0.75 ESR1 (0.46) CYP2C9CYP1A2ALDH1A1ESR1ESR2
SCHEMBL2158327 0.75 ESR1 (0.46) CYP2C9CYP1A2ALDH1A1ESR1ESR2
SCHEMBL1814746 0.75 KCNN4 (0.46) CYP2C9CYP1A2ALDH1A1ESR1ESR2
SCHEMBL28018612 0.75 PTPN1 (0.46) CYP2C9CYP1A2ALDH1A1PTPN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118063847-A High-sensitivity wearable chronic kidney disease detection gel and preparation method and application thereof 华南理工大学 2024-05-24 CN claimed
US-20140128420-A1 NUTRITIONAL SUPPLEMENT COMPOSITIONS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2014-05-08 US claimed
EP-1809283-A2 MORPHINE AND MORPHINE PRECURSORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2007-07-25 EP claimed
US-20060088607-A1 Nutritional supplement compositions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-04-27 US claimed
WO-2006039691-A2 MORPHINE AND MORPHINE PRECURSORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2006-04-13 WO claimed
EP-0632797-A4 PREPARATION OF SUBSTITUTED OR UNSUBSTITUTED PHENYLGLYOXALS. HOECHST CELANESE CORP (US) 1995-05-24 EP claimed
EP-0632797-A1 PREPARATION OF SUBSTITUTED OR UNSUBSTITUTED PHENYLGLYOXALS HOECHST CELANESE CORPORATION (US) 1995-01-11 EP claimed
US-5319142-A Process for preparing substituted and unsubstituted arylalkylamines HOECHST CELANESE CORPORATION (US) 1994-06-07 US claimed
WO-1993017989-A1 PREPARATION OF SUBSTITUTED OR UNSUBSTITUTED PHENYLGLYOXALS HOECHST CELANESE CORPORATION (US) 1993-09-16 WO claimed
US-5124489-A Process for preparing phenethanol ethers by the reduction of corresponding phenylglyoxal acetals HOECHST CELANESE CORPORATION (US) 1992-06-23 US claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 US disclosed
US-20250176872-A1 SYSTEMS AND METHODS FOR SENSING LEVODOPA DEXCOM, INC. (US) 2025-06-05 US disclosed
CN-118063847-A High-sensitivity wearable chronic kidney disease detection gel and preparation method and application thereof 华南理工大学 2024-05-24 CN disclosed
US-20230277125-A1 BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD UNIVERSITÄTS-KINDERSPITAL BEIDER BASEL (CH) 2023-09-07 US disclosed
WO-1993017989-A1 PREPARATION OF SUBSTITUTED OR UNSUBSTITUTED PHENYLGLYOXALS HOECHST CELANESE CORPORATION (US) 1993-09-16 WO disclosed
US-5124489-A Process for preparing phenethanol ethers by the reduction of corresponding phenylglyoxal acetals HOECHST CELANESE CORPORATION (US) 1992-06-23 US disclosed
US-5124489-A Process for preparing phenethanol ethers by the reduction of corresponding phenylglyoxal acetals HOECHST CELANESE CORPORATION (US) 1992-06-23 US disclosed
US-5124489-A Process for preparing phenethanol ethers by the reduction of corresponding phenylglyoxal acetals HOECHST CELANESE CORPORATION (US) 1992-06-23 US disclosed
US-4552680-A Hypochlorite bleach containing surfactant and organic antifoamant THE PROCTER & GAMBLE COMPANY (US) 1985-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 CYP2C9 1831/4885CYP1A2 2345/4885ALDH1A1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.